12:00 AM
 | 
Jul 20, 2015
 |  BC Week In Review  |  Company News  |  Other News

Allergan, Eli Lilly cancer news

The U.K. Court of Appeal ruled that Allergan’s pemetrexed salt formulations would indirectly infringe an Alimta pemetrexed vitamin dosing regimen patent. The patent covering vitamin dosing regimens of the antifolate that inhibits thymidylate synthase, ...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >